glp-1 drug side effects Receptor Agonists What Should I Expect the

Glucagon-like peptide1 receptor agonists (GLP-1RAs) have emerged as a transformative class of therapies initially developed for glycemic control in type2 diabetes mellitus

In crude analyses, GLP-1 receptor agonist use was associated with an increased incidence of suicidality compared with DPP-4 inhibitors (crude incidence rates 3.9 v 1.8 per 1000 person years, respectively

Quality Standards & Traceability

The glp-1 agonists market is expected to reach US$ 118,926.1 billion by 2032, growing at a significant CAGR of 18.1% from 2026 to 2032.

SAN DIEGO(March 10, 2025)Glucagon-like peptide-1 receptor agonists (GLP-1 agonists), such as semaglutide (e.g., Ozempic), have helped improve the management of type 2 diabetes and obesity

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health care spending.